Recent events
Recent events tied to this brand in public sources.
Back to profile16 entries
2022
BioNTech introduces BioNTainer manufacturing solution
BioNTech introduced its BioNTainer container-based approach for establishing scalable mRNA vaccine manufacturing facilities in Africa. Construction of the first facility was planned to start in mid-2022.
2021
FDA fully approves Pfizer/BioNTech COVID-19 vaccine
The FDA fully approved Pfizer/BioNTech's COVID-19 vaccine on August 23, 2021; the vaccine will be marketed as Comirnaty for prevention of COVID-19 in individuals aged 16 and older.
2021
Pfizer and BioNTech sign vaccine manufacturing letter of intent with Biovac
Pfizer and BioNTech signed a letter of intent with Biovac Institute to manufacture their COVID-19 vaccine at Biovac's Cape Town facility. The companies said the facility was expected to join their supply chain by the end of 2021, with finished-dose production planned to begin in 2022.
2021
BioNTech announces planned Southeast Asia expansion
BioNTech announced plans to expand its global footprint to Asia by establishing its first regional headquarters for Southeast Asia in Singapore, including an mRNA manufacturing facility.
2021
BioNTech vaccine batch paused in Hong Kong and Macau after vial-cap defect
BioNTech notified Fosun Pharma of a vial-cap defect in BNT162b2 batch 210102 supplied to Hong Kong and Macau. BioNTech and Fosun Pharma began investigating the cause, and the batch was paused for vaccination until the investigation ends; Fosun Pharma also said batch 210104 intended for Hong Kong would be stored and not sent to vaccination sites pending further notice.
2021
Evonik expands strategic partnership with BioNTech for vaccine lipids
Evonik and BioNTech expanded their strategic partnership to produce specialty lipids for COVID-19 vaccines at Evonik sites in Germany, with commercial quantities planned as early as the second half of 2021.
2021
Pfizer announces expanded COVID-19 vaccine production capacity
Pfizer CEO Albert Bourla said the company would use additional manufacturing capacity and work with new suppliers to increase production of its COVID-19 vaccine. The announced plans include additional capacity at its Kalamazoo, Groton and McPherson sites.
2021
BioNTech and Pfizer announce increased EU vaccine deliveries
BioNTech and Pfizer announced that they would increase coronavirus vaccine deliveries to the European Union, pledging up to 75 million additional doses in the spring. They said increased production capabilities would allow them to accelerate supplies.
2020
QIAGEN and BioNTech announce companion diagnostic collaboration
QIAGEN announced a strategic collaboration with BioNTech to develop and commercialize a tissue-based companion diagnostic for use with investigational cancer treatment BNT113.
2020
BioNTech and Regeneron announce melanoma trial collaboration
BioNTech announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech's BNT111 FixVac candidate and Regeneron's Libtayo for melanoma. The companies said they planned to jointly conduct a randomized Phase 2 study and share the trial's development costs equally.
2020
BioNTech announces equity offering pricing and rights offering terms
BioNTech announced pricing for an underwritten offering of 5.5 million American Depositary Shares at $93 each and announced terms for a rights offering of up to 7,505,596 ordinary shares.
2020
Pfizer and BioNTech collaborate on coronavirus vaccine testing
Pfizer Pharmaceuticals is working with BioNTech to test a coronavirus vaccine on people in Germany and the United States.
2020
BioNTech completed its acquisition of Neon Therapeutics
BioNTech announced the closing of its all-stock acquisition of Neon Therapeutics. Neon became a subsidiary based in Cambridge, Massachusetts, operating as BioNTech US Inc.
2020
BioNTech announces agreement to acquire Neon Therapeutics
BioNTech and Neon Therapeutics announced a definitive merger agreement under which BioNTech would acquire Neon in an all-stock transaction. The transaction was expected to close during the second quarter of 2020.
2020
BioNTech reports 2019 full-year financial results
BioNTech reported financial results for the quarter and full year ended December 31, 2019, and provided a corporate progress update.
2019
BioNTech announces pricing of its initial public offering
BioNTech announced the pricing of an initial public offering of 10,000,000 American Depositary Shares at $15.00 per share, for gross proceeds of $150 million. The ADSs were expected to begin trading on Nasdaq on October 10, 2019, and the offering was expected to close on October 15, subject to customary conditions.